99 related articles for article (PubMed ID: 25459666)
1. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint.
Yotsukura S; Mamitsuka H
Crit Rev Oncol Hematol; 2015 Feb; 93(2):103-15. PubMed ID: 25459666
[TBL] [Abstract][Full Text] [Related]
2. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.
Ren S; Wang F; Shen J; Sun Y; Xu W; Lu J; Wei M; Xu C; Wu C; Zhang Z; Gao X; Liu Z; Hou J; Huang J; Sun Y
Eur J Cancer; 2013 Sep; 49(13):2949-59. PubMed ID: 23726266
[TBL] [Abstract][Full Text] [Related]
5. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
6. Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens.
Draghici S; Chatterjee M; Tainsky MA
Expert Rev Mol Diagn; 2005 Sep; 5(5):735-43. PubMed ID: 16149876
[TBL] [Abstract][Full Text] [Related]
7. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
8. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit].
Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H
Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
10. Detection of hypopharyngeal squamous cell carcinoma using serum proteomics.
Zhou L; Cheng L; Tao L; Jia X; Lu Y; Liao P
Acta Otolaryngol; 2006 Aug; 126(8):853-60. PubMed ID: 16846929
[TBL] [Abstract][Full Text] [Related]
11. Serum ceruloplasmin in melanoma patients.
Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
Anticancer Res; 2001; 21(1B):629-32. PubMed ID: 11299817
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
13. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
[TBL] [Abstract][Full Text] [Related]
14. Improving the biomarker pipeline to develop and evaluate cancer screening tests.
Baker SG
J Natl Cancer Inst; 2009 Aug; 101(16):1116-9. PubMed ID: 19574417
[TBL] [Abstract][Full Text] [Related]
15. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
Zhao H; Shi X; Liu J; Chen Z; Wang G
J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
[TBL] [Abstract][Full Text] [Related]
16. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
17. Novel serum nucleosomics biomarkers for the detection of colorectal cancer.
Holdenrieder S; Dharuman Y; Standop J; Trimpop N; Herzog M; Hettwer K; Simon K; Uhlig S; Micallef J
Anticancer Res; 2014 May; 34(5):2357-62. PubMed ID: 24778043
[TBL] [Abstract][Full Text] [Related]
18. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
Bertenshaw GP; Yip P; Seshaiah P; Zhao J; Chen TH; Wiggins WS; Mapes JP; Mansfield BC
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2872-81. PubMed ID: 18843033
[TBL] [Abstract][Full Text] [Related]
19. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
20. Combining biomarkers to detect disease with application to prostate cancer.
Etzioni R; Kooperberg C; Pepe M; Smith R; Gann PH
Biostatistics; 2003 Oct; 4(4):523-38. PubMed ID: 14557109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
